Paper Details

  1. Home
  2. Paper Details

Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.

Author: MeaseP J

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Etanercept, a medication that blocks tumor necrosis factor (TNF), was approved to treat psoriatic arthritis (PsA) in 2002. It works by preventing TNF from interacting with cells, reducing inflammation. Two studies, involving a total of 265 patients, found etanercept to be more effective than placebo in treating PsA, with improvements in PsA symptoms and skin lesions. Side effects were minimal, with about a quarter of patients experiencing mild injection site reactions that resolved with continued treatment. Etanercept appears to be a safe and effective treatment for PsA, with a safety profile similar to its use in rheumatoid arthritis.
Paper Details　
Original Abstract of the Article :
Etanercept (Enbrel, Amgen and Wyeth), a tumor necrosis factor (TNF) antagonist, was approved in January 2002, for the treatment of psoriatic arthritis (PsA). The anti-inflammatory effects of etanercept are due to its ability to bind to the pro-inflammatory cytokine TNF, preventing it from interactin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/12728284

データ提供：米国国立医学図書館（NLM）

Etanercept: A TNF Antagonist for the Treatment of Psoriatic Arthritis and Psoriasis

My friend, we're delving into the world of [rheumatology] and looking at a fascinating drug, [etanercept]. This study used a classic [randomized controlled trial] to assess its efficacy in treating [psoriatic arthritis] and [psoriasis]. It's like exploring a vast desert, searching for the oasis of effective treatment! The researchers discovered that [etanercept] is significantly more effective than a placebo in treating both conditions, a finding that's sure to be a welcome relief for those with these inflammatory diseases. The results were evaluated using the [Psoriatic Arthritis Response Criteria] and the [American College of Rheumatology] criteria for PsA, and the [Psoriasis Area and Severity Index] for psoriasis. It's like finding a wellspring of hope in the desert.

A Promising Treatment for Psoriatic Arthritis and Psoriasis

This research is a beacon of hope for those dealing with the often-debilitating symptoms of [psoriatic arthritis] and [psoriasis]. It demonstrates that [etanercept] can provide significant relief for patients, a finding that's likely to have a profound impact on their quality of life.

Understanding the Health Implications and Potential Side Effects

It's important to remember that, like any medication, [etanercept] can have side effects. The study notes that approximately one-quarter of the patients experienced mild [injection site reactions], which thankfully resolved during continued therapy. Just like a desert can have unexpected storms, any medication can come with some side effects. But the good news is that [etanercept] is generally well tolerated by patients, and the benefits often outweigh the risks.

Dr. Camel's Conclusion

The research on [etanercept] provides a promising avenue for treating [psoriatic arthritis] and [psoriasis]. It's important to consult with a healthcare professional to determine if this medication is right for you, as it's always best to weigh the benefits against the risks.
Date :
  1. Date Completed 2003-07-16
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

12728284

DOI: Digital Object Identifier

12728284

Related Literature

Article Analysis
・Effective treatment of psoriatic arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.